Breaking News Instant updates and real-time market news.

2022-05-19 16:11:48 BSY Bentley Systems $32.35 / +1.5 (+4.86%) 16:11 05/19/22 05/19 16:11 05/19/22 16:11	Bentley Systems initiated with an Outperform at Oppenheimer Oppenheimer analyst Kristen Owen initiated coverage of Bentley Systems with an Outperform rating and $40 price target.	26 May

2022-05-19 16:11:48

BSY

Bentley Systems

$32.35 / +1.5 (+4.86%)

16:11

05/19/22

05/19

16:11

05/19/22

16:11

Bentley Systems initiated with an Outperform at Oppenheimer

Oppenheimer analyst Kristen Owen initiated coverage of Bentley Systems with an Outperform rating and $40 price target.

26
May

OTHER BREAKING NEWS FROM THE FLY

Upgrade	Anhui Conch Cement upgraded to Neutral from Sell at Goldman Sachs » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) 11/15/22 HSBC Anhui Conch Cement upgraded to Buy from Hold at HSBC 08/28/22 Goldman Sachs Anhui Conch Cement downgraded to Sell from Neutral at Goldman Sachs
Hot Stocks	Kala Pharmaceuticals appoints Francis Mah as chief medical advisor » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) Kala Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/27/23 Kala announces safety update from Cohort 1 of CHASE Phase 2b trial 02/14/23 Kala recruiting for study of KPI-012 in participants with PCED 01/19/23 Kala Pharmaceuticals falls 10% to $15.90 after equity offering 12/30/22 Kala Pharmaceuticals trading resumes KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/06/23 H.C. Wainwright Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright 12/29/22 Wedbush IND acceptance sets up Kala for execution year in 2023, says Wedbush 11/09/22 Wedbush Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush 05/24/22 H.C. Wainwright Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/03/23 Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year 11/08/22 Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 01/19/23 Fly Intel: After-Hours Movers 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 Fly Intel: After-Hours Movers 04/24/23 Kala Pharmaceuticals, Inc.
Hot Stocks	NV5 awarded $11M essential infrastructure projects in California, New Mexico » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 NVEE NV5 Global $100.90 / +0.02 (+0.02%) NV5 Global announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVEE NV5 Global $100.90 / +0.02 (+0.02%) 03/13/23 NV5 Global announces $11M in engineering, planning awards 03/06/23 NV5 Global announces Axim Geospatial awarded $9M in national security contracts 03/02/23 NV5 Global acquires Gaudet Associates 02/23/23 NV5 Global announces acquisition of Axim Geospatial NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/24/23 Baird NV5 Global price target lowered to $130 from $150 at Baird 08/05/22 Lake Street NV5 Global price target raised to $175 from $136 at Lake Street NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/23/23 NV5 Global reports Q4 EPS $1.21 , consensus $1.57 11/03/22 NV5 Global reports Q3 adjusted EPS $1.50, consensus $1.45
Hot Stocks	DoubleDown announces results of 2023 Annual General Meeting » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 DDI DoubleDown $8.09 / +0.08 (+1.00%) DoubleDown Interactive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research DDI DoubleDown $8.09 / +0.08 (+1.00%) 01/11/23 DoubleDown to acquire i-Gaming company SuprNation for $35M 12/28/22 DoubleDown announces results of EGM held on December 28 DDI DoubleDown $8.09 / +0.08 (+1.00%) 09/15/22 Macquarie DoubleDown initiated with an Outperform at Macquarie 07/11/22 B. Riley Investors have overlooked DoubleDown, says B. Riley 06/28/22 B. Riley DoubleDown price target lowered to $20 from $30 at B. Riley
Initiation	Engie Brasil initiated with an Outperform at Scotiabank » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) Scotiabank analyst Renato… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) 03/07/23 UBS Engie Brasil upgraded to Buy from Neutral at UBS 01/10/23 JPMorgan Engie Brasil upgraded to Overweight from Neutral at JPMorgan 10/14/22 JPMorgan Engie Brasil upgraded to Neutral from Underweight at JPMorgan 08/08/22 JPMorgan Engie Brasil downgraded to Underweight from Neutral at JPMorgan
Recommendations	LuxUrban Hotels price target raised to $7 from $6 at Maxim » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 02/16/23 LuxUrban Hotels announces preferred U.S.hotel partnership with NusaTrip 02/08/23 LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms 12/02/22 LuxUrban Hotels names Jimmie Chatmon COO 12/01/22 LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 12/12/22 Maxim LuxUrban Hotels initiated with a Buy at Maxim LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 01/18/23 LuxUrban Hotels affirms FY22 net rental revenue and EBITDA guidance
Hot Stocks	Rapt Therapeutics announces initiation of Phase 2a trial of RPT193 » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) RAPT Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/10/23 Rapt Therapeutics says $2M of cash held at Silicon Valley Bank 12/08/22 Rapt Therapeutics reports Phase 1/2 results of FLX475 in advanced cancer 11/17/22 Rapt Therapeutics falls 7% to $19.70 after $75M common stock offering RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/15/23 Capital One Rapt outlook 'remains steady' despite shift in timeline, says Capital One 03/15/23 Cantor Fitzgerald Rapt Therapeutics price target lowered to $40 from $44 at Cantor Fitzgerald 03/15/23 H.C. Wainwright Rapt Therapeutics price target lowered to $43 from $50 at H.C. Wainwright 01/04/23 Guggenheim Rapt Therapeutics initiated with a Buy at Guggenheim RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/14/23 Rapt Therapeutics reports Q4 EPS (64c), consensus (66c) 11/10/22 Rapt Therapeutics reports Q3 EPS (63c), consensus (67c) 18 Nov RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/16/23 Biotech Alert: Searches spiking for these stocks today 11/17/22 Fly Intel: After-Hours Movers
Hot Stocks	Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) Harmony Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' 01/09/23 Novavax names John Jacobs as new CEO, succeeding Stanley Erck 01/06/23 Harmony Biosciences CEO John Jacobs stepping down 11/15/22 Harmony Biosciences director sells $9.12M in common stock HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Mizuho Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 03/28/23 Raymond James Raymond James says buy Harmony on weakness after 'low quality' short report 02/22/23 Mizuho Harmony Biosciences price target lowered to $60 from $70 at Mizuho 01/04/23 Piper Sandler Harmony Biosciences price target raised to $70 from $62 at Piper Sandler HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 02/21/23 Harmony Biosciences reports Q4 non-GAAP EPS $1.01, consensus 58c 11/01/22 Harmony Biosciences reports Q3 non-GAAP EPS 95c vs 41c last year HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Scorpion: Filing Citizen's Petition to request withdrawal of Harmony drug 03/28/23 Scorpion Capital issues investigative report on Harmony Biosciences HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/28/23 Harmony plunges as Scorpion seeks FDA withdrawal of Wakix approval 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Pacira announces FDA clearance of sNDA for EXPAREL label » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PCRX Pacira $39.93 / -0.15 (-0.37%) Pacira BioSciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PCRX Pacira $39.93 / -0.15 (-0.37%) 03/27/23 Court upholds decision to dismiss Pacira lawsuit against ASA 03/22/23 Pacira announces Yvonne Greenstreet to retire from Board 02/28/23 Pacira sees 2023 EXPAREL net sales $570M-$580M 02/23/23 Pacira, LPGA partner to raise awareness of non-opioid pain management solutions PCRX Pacira $39.93 / -0.15 (-0.37%) 03/03/23 Barclays Pacira price target lowered to $80 from $90 at Barclays 03/01/23 H.C. Wainwright Pacira price target raised to $71 from $69 at H.C. Wainwright 02/10/23 H.C. Wainwright Pacira price target lowered to $69 from $76 at H.C. Wainwright 01/31/23 Wedbush Pacira assumed with an Outperform at Wedbush PCRX Pacira $39.93 / -0.15 (-0.37%) 02/28/23 Pacira reports Q4 adjusted EPS 80c, consensus 83c 01/05/23 Pacira sees FY22 EPS 'at least' $2.50, consensus $2.77 11/03/22 Pacira reports Q3 adjusted EPS 64c, consensus 76c 10/13/22 Pacira reports preliminary Q3 revenue $167.5M, consensus $172.72M
Hot Stocks	Baltimore Orioles select Shift4 to process payments for ballpark concessions » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) "We're thrilled… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments rises 9.1% 01/17/23 Shift4 Payments partners with Real Salt Lake 11/22/22 Shift4 Payments falls -8.5% 11/07/22 Shift4 Payments rises 10.6% FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/16/23 Truist Shift4 Payments price target raised to $87 from $80 at Truist 03/01/23 RBC Capital Shift4 Payments price target raised to $80 from $70 at RBC Capital 03/01/23 Piper Sandler Shift4 Payments price target raised to $85 from $69 at Piper Sandler 03/01/23 DA Davidson Shift4 Payments price target raised to $80 from $65 at DA Davidson FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments sees FY23 revenue $2.5B-$2.7B. consensus $2.74B 02/28/23 Shift4 Payments reports Q4 adjusted EPS 47c, consensus 38c 02/27/23 Notable companies reporting before tomorrow's open 02/27/23 Notable companies reporting before tomorrow's open FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Fly Intel: Pre-market Movers 12/30/22 Buy/Sell: Wall Street's top 5 stock calls this week 12/29/22 What You Missed On Wall Street On Thursday 12/29/22 What You Missed On Wall Street This Morning FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/28/23 Shift4 Payments call volume above normal and directionally bullish 03/03/23 Shift4 Payments put volume heavy and directionally bearish 03/01/23 Shift4 Payments call volume above normal and directionally bullish

Hot Stocks	Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007 » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PGEN Precigen / + Precigen announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PGEN Precigen / + 01/24/23 Precigen reports results from Phase 1 PRGN-2012 study 01/11/23 Precigen CEO says will focus on clinical programs' path to licensure in 2023 12/12/22 Precigen announces 'positive' Phase 1 dose escalation data from PRGN-3006 study PGEN Precigen / + 01/30/23 Cantor Fitzgerald Precigen price target raised to $10 from $7 at Cantor Fitzgerald 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald PGEN Precigen / + 03/06/23 Precigen reports Q4 EPS (11c), consensus (10c) 11/09/22 Precigen reports Q3 EPS (4c), consensus 2c 25 Jan PGEN Precigen / + 01/27/23 Biotech Alert: Searches spiking for these stocks today 01/25/23 What You Missed On Wall Street On Wednesday 01/25/23 What You Missed On Wall Street This Morning 01/25/23 Fly Intel: Pre-market Movers PGEN Precigen / + 03/06/23 Precigen options imply 35.3% move in share price post-earnings 02/08/23 Largest borrow rate increases among liquid names
Hot Stocks	Third Harmonic Bio expects cash to fund requirements through next 12 months » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/16/22 Jefferies Third Harmonic Bio downgraded to Hold from Buy at Jefferies 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 08:06 Today Third Harmonic Bio reports 2022 EPS ($2.62), consensus ($2.39) 15 Sep THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning
Recommendations	Biolase price target lowered to $1 from $5 at Maxim » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 BIOL Biolase / + Maxim analyst Anthony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BIOL Biolase / + 01/04/23 Sonendo unit files patent infringement lawsuit against Biolase BIOL Biolase / + 01/20/23 Lake Street Biolase assumed with a Buy at Lake Street 11/11/22 Maxim Biolase price target lowered to $5 from $10 at Maxim 05/20/22 Lake Street Biolase initiated with a Buy at Lake Street BIOL Biolase / + 03/28/23 Biolase sees Q1 revenue over $10.0M, consensus $12.23M 03/28/23 Biolase reports Q4 EPS ($1.28), consensus (64c) 01/18/23 Biolase targets revenue growth by at least 25% in 2023, consensus $55.06M 01/18/23 Biolase sees 2022 revenue $48.4M-$48.8M, consensus $47.58M
Hot Stocks	ProQR announces initial pipeline targets, highlights Axiomer platfotform » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) ProQR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 03/14/23 ProQR Therapeutics announces successful defense of Axiomer patent pending 03/07/23 ProQR Therapeutics to present on Axiomer RNA editing technology platform 12/22/22 Eli Lilly, ProQR expand genetic medicines licensing and collaboration agreement 12/22/22 Eli Lilly, ProQR Therapeutics to expand RNA editing collaboration PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 03/10/23 Stifel Stifel says SVB fallout 'appears limited' across firm's biotech coverage 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 12/23/22 Raymond James ProQR Therapeutics price target raised to $5 from $2 at Raymond James 12/22/22 JMP Securities ProQR Therapeutics shares remain 'fairly valued,' says JMP Securities PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 11/09/22 ProQR Therapeutics reports Q3 EPS (EUR 0.34) vs (EUR 0.22) last year PRQR ProQR Therapeutics $3.58 / -0.02 (-0.56%) 12/22/22 Fly Intel: Pre-market Movers 10:00 Today ProQR Therapeutics - PRQR
Hot Stocks	EzFill and SaverOne 2014 launch driving safety pilot program in Florida » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 SVRE SaverOne 2014 $1.15 / +0.02 (+1.77%) , EZFL EzFill / + EzFill (EZFL) announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings SVRE EZFL SVRE SaverOne 2014 $1.15 / +0.02 (+1.77%) 03/23/23 SaverOne 2014 signs agreement with Moviley Dror involving 150 delivery trucks 03/08/23 SaverOne 2014 signs agreement with Electra Afikim 01/19/23 SaverOne 2014's safe driving system adopted by Israeli supermarket Shufersal 01/17/23 SaverOne 2014 collaborating with Israeli auto importer for safe driving system EZFL EzFill / + 03/03/23 EzFill adds 10 fleet accounts in February 02/23/23 EzFill named Arbour to board of directors 02/21/23 EzFill signs agreement with South Florida Motorsports 01/30/23 EzFill to launch EzFill NOW Program EZFL EZFL EzFill / + 02/10/23 EzFill reports preliminary Q4 revenue $4.9M vs. $2M last year 11/08/22 EzFill reports Q3 EPS (15c) vs. (13c) last year
Earnings	Third Harmonic Bio reports 2022 EPS ($2.62), consensus ($2.39) » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) "Given the promising… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/16/22 Jefferies Third Harmonic Bio downgraded to Hold from Buy at Jefferies 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley 15 Sep THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning
Hot Stocks	Establishment Labs has surpassed three million Motiva devices in market » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 ESTA Establishment Labs $68.73 / -1.89 (-2.68%) Establishment Labs… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly ESTA Establishment Labs $68.73 / -1.89 (-2.68%) 01/03/23 Establishment Labs enters Mia Femtech agreement in Japan 11/10/22 Establishment Labs announces Japan PMDA approval for Motiva Implants 10/19/22 Establishment Labs sinks 18% after Hindenburg short report ESTA Establishment Labs $68.73 / -1.89 (-2.68%) 01/24/23 Mizuho Establishment Labs price target raised to $95 from $70 at Mizuho 12/28/22 Stephens Establishment Labs price target lowered to $87 from $90 at Stephens 12/28/22 Stephens Cutera price target lowered to $68 from $78 at Stephens 10/21/22 B. Riley B. Riley sees 'major tailwind' for Establishment Labs in 2023 ESTA Establishment Labs $68.73 / -1.89 (-2.68%) 02/27/23 Establishment Labs reports Q4 EPS (55c), consensus (68c) 01/09/23 Establishment Labs reports preliminary Q4 revenue $43.3M-$44.4M 11/07/22 Establishment Labs narrows FY22 revenue view to $158M-$162M, consensus $160.5M 11/07/22 Establishment Labs reports Q3 EPS (76c), consensus (54c) ESTA Establishment Labs $68.73 / -1.89 (-2.68%) 10/19/22 Hindenburg shorts Establishment Labs, sees 90% long-term downside 10/19/22 Hindenburg Research announces short position in Establishment Labs ESTA Establishment Labs $68.73 / -1.89 (-2.68%) 03/10/23 Sell these stocks now, proven algorithm says 02/27/23 Fly Intel: After-Hours Movers 11/25/22 Sell these stocks now, proven algorithm says 10/19/22 What You Missed On Wall Street On Wednesday
Periodicals	FDIC taps Newmark to sell Signature Bank loans, WSJ reports » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 SBNY Signature Bank $69.97 / + (+0.00%) , NMRK Newmark $6.46 / -0.04 (-0.62%) The FDIC has selected… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SBNY NMRK SBNY Signature Bank $69.97 / + (+0.00%) 03/27/23 FDIC investigating misconduct in management of SVB Financial, Signature Bank 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/22/23 Stronghold Digital reports no direct exposure to SVB, Signature, Silvergate 03/20/23 WhiteHorse Finance says no exposure to Silicon Valley Bank or Signature Bank NMRK Newmark $6.46 / -0.04 (-0.62%) 03/10/23 Newmark acquires real estate advisory firm, Gerald Eve, no terms disclosed 01/17/23 Frontier appoints Newmark to manage its real-estate portfolio 12/08/22 Newmark arranges $300M self storage joint venture 10/06/22 Newmark names Angie Leccese as chief marketing officer SBNY NMRK SBNY Signature Bank $69.97 / + (+0.00%) 03/24/23 Morgan Stanley nCino price target lowered to $27 from $35 at Morgan Stanley 03/22/23 BofA Regional bank distress gives CME Group a new growth opportunity, says BofA 03/22/23 Raymond James New York Community Bancorp resumed with a Strong Buy at Raymond James 03/20/23 BofA New York Community's Signature deal 'could be a significant positive,' says BofA NMRK Newmark $6.46 / -0.04 (-0.62%) 12/12/22 Goldman Sachs Newmark downgraded to Sell from Neutral at Goldman Sachs 10/07/22 Piper Sandler Newmark price target lowered to $10 from $12 at Piper Sandler 04/18/22 Piper Sandler Newmark downgraded to Neutral from Overweight at Piper Sandler 04/05/22 Goldman Sachs Newmark initiated with a Neutral at Goldman Sachs SBNY NMRK SBNY Signature Bank $69.97 / + (+0.00%) 01/17/23 Signature Bank reports Q4 EPS $4.65, consensus $4.89 10/18/22 Signature Bank reports Q3 EPS $5.57, consensus $5.41 10/17/22 Notable companies reporting before tomorrow's open 10/17/22 Notable companies reporting before tomorrow's open NMRK Newmark $6.46 / -0.04 (-0.62%) 02/16/23 Newmark sees FY23 revenue $2.5B- $2.7B, consensus $2.58B 02/16/23 Newmark sees Q1 revenue $500M-$550M, consensus $563.39M 02/16/23 Newmark reports Q4 adjusted EPS 32c, consensus 32c 10/28/22 Newmark lowers FY22 revenue view to $2.7B-$2.8B from $3.0B-$3.1B SBNY NMRK SBNY Signature Bank $69.97 / + (+0.00%) 03/26/23 Banking stress puts U.S., Europe on watch for credit crunch, Reuters says 03/21/23 $8T mortgage-debt market to be impacted after SVB collapse, WSJ reports 03/17/23 BofA not interested in acquiring Signature Bank, Reuters reports 03/17/23 FDIC open to sharing losses to smooth sale of SVB, Signature, FT says NMRK Newmark $6.46 / -0.04 (-0.62%) 02/15/23 Cushman & Wakefield commercial brokerage team heads to Newmark, WSJ says SBNY NMRK SBNY Signature Bank $69.97 / + (+0.00%) 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning 03/17/23 Here's What You Missed in Crypto This Week 03/15/23 What You Missed On Wall Street On Wednesday NMRK Newmark $6.46 / -0.04 (-0.62%) 10/28/22 What You Missed On Wall Street This Morning 05/12/23 2023 Real Estate Summit 04/19/23 Signature Bank SBNY SBNY Signature Bank $69.97 / + (+0.00%) 03/20/23 Largest borrow rate increases among liquid names 03/09/23 Signature Bank put volume heavy and directionally bearish 01/18/23 Signature Bank put volume heavy and directionally bearish 01/18/23 Early notable gainers among liquid option names on January 18th
Downgrade	Maxim downgrades Monopar on termination of lead asset Validive » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 MNPR Monopar Therapeutics $1.43 / -1.47 (-50.69%) Maxim analyst Jason… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings MNPR Monopar Therapeutics $1.43 / -1.47 (-50.69%) 03/27/23 Monopar Therapeutics Inc trading resumes 03/27/23 Monopar completes interim analysis of Phase 2b/3 VOICE trial 03/27/23 Monopar Therapeutics Inc trading halted, news pending 02/27/23 Monopar Therapeutics, NorthStar announces expanded radiopharma program MNPR Monopar Therapeutics $1.43 / -1.47 (-50.69%) 07:41 Today Maxim Monopar Therapeutics downgraded to Hold from Buy at Maxim 01/23/23 EF Hutton Monopar Therapeutics initiated with a Buy at EF Hutton 12/09/22 Roth Capital Monopar Therapeutics resumed with a Buy at Roth Capital 08/16/22 H.C. Wainwright Monopar Therapeutics price target lowered to $6 from $9 at H.C. Wainwright MNPR Monopar Therapeutics $1.43 / -1.47 (-50.69%) 03/23/23 Monopar Therapeutics reports Q4 EPS (22c), consensus (20c) 11/10/22 Monopar Therapeutics reports Q3 EPS (19c), consensus (22c)
Earnings	UniFirst sees 2023 EPS $5.02-$5.37, consensus $7.55 » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 UNF UniFirst $192.81 / +1.12 (+0.58%) Sees revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events UNF UniFirst $192.81 / +1.12 (+0.58%) 02/08/23 UniFirst to acquire Clean Uniform for $300M 10/25/22 UniFirst increases quarterly common stock dividend to 31c per share UNF UniFirst $192.81 / +1.12 (+0.58%) 01/05/23 Baird UniFirst price target raised to $225 from $199 at Baird 05/18/22 Baird UniFirst price target lowered to $195 from $213 at Baird 04/01/22 JPMorgan UniFirst downgraded to sell on missed earnings pattern at JPMorgan 04/01/22 JPMorgan UniFirst downgraded to Underweight from Neutral at JPMorgan UNF UniFirst $192.81 / +1.12 (+0.58%) 08:03 Today UniFirst reports Q2 EPS 95c, consensus $1.38 01/04/23 UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.21 01/04/23 UniFirst reports Q1 adjusted EPS $2.21, consensus $1.94 10/19/22 UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.72 UNF UniFirst $192.81 / +1.12 (+0.58%) 01/04/23 What You Missed On Wall Street On Wednesday 01/04/23 What You Missed On Wall Street This Morning 09:00 Today UniFirst - UNF

Downgrade	Generation Income Properties cut to Hold at Maxim, no dividend coverage expected » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 GIPR Generation Income Properties $4.75 / +0.07 (+1.50%) Maxim downgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research GIPR Generation Income Properties $4.75 / +0.07 (+1.50%) 07:41 Today Maxim Generation Income Properties downgraded to Hold from Buy at Maxim
Earnings	Cocrystal Pharma reports FY22 ($4.77), consensus ($4.10) » 08:05 03/29/23 03/29 08:05 03/29/23 08:05 COCP Cocrystal Pharma $1.80 / -0.08 (-4.26%) "This is an eventful… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings COCP Cocrystal Pharma $1.80 / -0.08 (-4.26%) 12/19/22 Cocrystal reports safety, tolerability results from Phase 1 study of CC-42344 11/17/22 Cocrystal Pharma announces safety data from Phase 1 study with CC-42344 11/01/22 Cocrystal Pharma granted European patent covering CC-42344 10/26/22 Cocrystal Pharma completes enrollment in Phase 1 study of CC-42344 COCP Cocrystal Pharma $1.80 / -0.08 (-4.26%) 01/24/23 H.C. Wainwright Cocrystal Pharma price target lowered to $35 from $42 at H.C. Wainwright COCP Cocrystal Pharma $1.80 / -0.08 (-4.26%) 11/14/22 Cocrystal Pharma reports Q3 EPS (70c), consensus (48c)
Hot Stocks	Honeywell invests in Energy-as-a-Service provider Redaptive » 08:04 03/29/23 03/29 08:04 03/29/23 08:04 HON Honeywell $187.86 / -0.12 (-0.06%) Honeywell announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options HON Honeywell $187.86 / -0.12 (-0.06%) 03/14/23 Honeywell says Vimal Kapur to succeed Darius Adamczyk as CEO on June 1 03/14/23 Honeywell says Vimal Kapur to succeed Darius Adamczyk as CEO on June 1 02/06/23 TAT Technologies extends contract with global air carrier 02/02/23 Honeywell expects Q1 to be most supply constrained of the year HON Honeywell $187.86 / -0.12 (-0.06%) 02/28/23 UBS Honeywell price target lowered to $185 from $193 at UBS 02/14/23 HSBC Honeywell price target raised to $205 from $190 at HSBC 02/09/23 Credit Suisse Zebra Technologies downgraded to Neutral from Outperform at Credit Suisse 02/03/23 Deutsche Bank Honeywell price target lowered to $235 from $242 at Deutsche Bank HON Honeywell $187.86 / -0.12 (-0.06%) 02/02/23 Honeywell sees Q1 adjusted EPS $1.86-$1.96, consensus $2.03 02/02/23 Honeywell sees FY23 adjusted EPS $8.80-$9.20, consensus $9.13 02/02/23 Honeywell reports Q4 adjusted EPS $2.52, consensus $2.51 02/01/23 Notable companies reporting before tomorrow's open HON Honeywell $187.86 / -0.12 (-0.06%) 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 02/02/23 Fly Intel: Pre-market Movers 01/04/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations HON Honeywell $187.86 / -0.12 (-0.06%) 01/18/23 Honeywell put volume heavy and directionally bearish
Earnings	UniFirst reports Q2 EPS 95c, consensus $1.38 » 08:03 03/29/23 03/29 08:03 03/29/23 08:03 UNF UniFirst $192.81 / +1.12 (+0.58%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events UNF UniFirst $192.81 / +1.12 (+0.58%) 02/08/23 UniFirst to acquire Clean Uniform for $300M 10/25/22 UniFirst increases quarterly common stock dividend to 31c per share UNF UniFirst $192.81 / +1.12 (+0.58%) 01/05/23 Baird UniFirst price target raised to $225 from $199 at Baird 05/18/22 Baird UniFirst price target lowered to $195 from $213 at Baird 04/01/22 JPMorgan UniFirst downgraded to sell on missed earnings pattern at JPMorgan 04/01/22 JPMorgan UniFirst downgraded to Underweight from Neutral at JPMorgan UNF UniFirst $192.81 / +1.12 (+0.58%) 01/04/23 UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.21 01/04/23 UniFirst reports Q1 adjusted EPS $2.21, consensus $1.94 10/19/22 UniFirst sees 2023 adjusted EPS $7.10-$7.50, consensus $7.72 10/19/22 UniFirst reports Q4 adjusted EPS $1.79, consensus $1.73 UNF UniFirst $192.81 / +1.12 (+0.58%) 01/04/23 What You Missed On Wall Street On Wednesday 01/04/23 What You Missed On Wall Street This Morning 09:00 Today UniFirst - UNF
Hot Stocks	Curaleaf to acquire Deseret Wellness for $20M » 08:02 03/29/23 03/29 08:02 03/29/23 08:02 CURLF Curaleaf $2.95 / -0.0042 (-0.14%) Curaleaf Holdings… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CURLF Curaleaf $2.95 / -0.0042 (-0.14%) 03/24/23 Curaleaf to delay Q4, FY earnings release, conference call 01/26/23 Curaleaf closes operations in California, Colorado and Oregon, cuts payroll 10% 01/24/23 Curaleaf expands Grassroots premium cannabis brand to New Jersey 01/12/23 Curaleaf opens Palm Beach Gardens dispensary CURLF Curaleaf $2.95 / -0.0042 (-0.14%) 02/08/23 Stifel Curaleaf price target lowered to C$8 from C$8.50 at Stifel 12/30/22 Cantor Fitzgerald Curaleaf price target lowered to $12 from $13 at Cantor Fitzgerald 12/01/22 Wedbush Wedbush starts Curaleaf with Outperform, expects share gains 12/01/22 Wedbush Curaleaf initiated with an Outperform at Wedbush CURLF Curaleaf $2.95 / -0.0042 (-0.14%) 11/07/22 Curaleaf reports Q3 EPS (7c), consensus (4c) CURLF Curaleaf $2.95 / -0.0042 (-0.14%) 01/26/23 Here's What You Missed in Cannabis, Psychedelics This Week 01/12/23 Here's What You Missed in Cannabis This Week 11/25/22 Rising High: Exclusive talk with cannabis REIT NewLake Capital

Events

Earnings calls, analyst events, roadshows and more

GLYC
Today at 08:30

GlycoMimetics - GLYC Conference Calls
MINM
Today at 08:30

Minim - MINM Conference Calls
BLUE
Today at 08:30

Bluebird Bio - BLUE Conference Calls
BTMD
Today at 08:30

Biote - BTMD Conference Calls
UNF
Today at 09:00

UniFirst - UNF Conference Calls
RDW
Today at 09:00

Redwire - RDW Conference Calls
BOSC
Today at 09:00

BOS Better Online Solutions - BOSC Conference Calls
IBEX
Today at 09:00

Ibex - IBEX Conference Calls
CLH
Today at 09:00

Clean Harbors Firm Sponsored Meetings

Virtual Meeting
PAYX
Today at 09:30

Paychex - PAYX Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	YGF X YGF YanGuFang IPO Managers: EF Hutton Priced at: $4.00 2M Shares ZJYL X ZJYL Jin Medical IPO Managers: Prime Number Priced at: $8.00 1M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	SYT X SYT Syla Technologies IPO Managers: Boustead $8.00 1.875M Shares
Fri	No deals

View All Syndicate Announcements »

Bentley Systems initiated with an Outperform at Oppenheimer

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access